Stephen Wiley's questions to Abcellera Biologics Inc (ABCL) leadership • Q2 2025
Question
Josh, on behalf of Stephen Wiley, questioned the strategy of using only Canadian sites for the ABCL575 Phase I trial and whether US sites would be added later. He also asked for potential autoimmune indications for the new pipeline asset, ABCL688.
Answer
CEO Carl Hansen confirmed the Phase I trial for ABCL575 is focused on an expert Canadian site, which is sufficient for the study's goals. He noted the company is engaging with the FDA for future Phase II studies which would likely include US sites. Regarding ABCL688, he declined to disclose the indication for strategic reasons but described it as a high-conviction program.